- Home
- MMLP vs KYTX Comparison
MMLP vs KYTX Comparison
Compare MMLP & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMLP
- KYTX
- Stock Information
- Founded
- MMLP 2002
- KYTX 2018
- Country
- MMLP United States
- KYTX United States
- Employees
- MMLP N/A
- KYTX N/A
- Industry
- MMLP Oil Refining/Marketing
- KYTX
- Sector
- MMLP Energy
- KYTX
- Exchange
- MMLP Nasdaq
- KYTX NYSE
- Market Cap
- MMLP 139.6M
- KYTX 119.7M
- IPO Year
- MMLP 2002
- KYTX 2024
- Fundamental
- Price
- MMLP $2.87
- KYTX $3.89
- Analyst Decision
- MMLP
- KYTX Strong Buy
- Analyst Count
- MMLP 0
- KYTX 5
- Target Price
- MMLP N/A
- KYTX $19.00
- AVG Volume (30 Days)
- MMLP 15.6K
- KYTX 682.4K
- Earning Date
- MMLP 07-16-2025
- KYTX 08-11-2025
- Dividend Yield
- MMLP 0.67%
- KYTX N/A
- EPS Growth
- MMLP N/A
- KYTX N/A
- EPS
- MMLP N/A
- KYTX N/A
- Revenue
- MMLP $715,480,000.00
- KYTX N/A
- Revenue This Year
- MMLP $4.19
- KYTX N/A
- Revenue Next Year
- MMLP N/A
- KYTX N/A
- P/E Ratio
- MMLP N/A
- KYTX N/A
- Revenue Growth
- MMLP N/A
- KYTX N/A
- 52 Week Low
- MMLP $2.56
- KYTX $1.78
- 52 Week High
- MMLP $4.13
- KYTX $11.24
- Technical
- Relative Strength Index (RSI)
- MMLP 44.01
- KYTX 62.86
- Support Level
- MMLP $2.85
- KYTX $3.63
- Resistance Level
- MMLP $3.03
- KYTX $4.45
- Average True Range (ATR)
- MMLP 0.07
- KYTX 0.38
- MACD
- MMLP -0.01
- KYTX 0.09
- Stochastic Oscillator
- MMLP 40.00
- KYTX 81.87
About MMLP Martin Midstream Partners L.P. Limited Partnership
Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.